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People who can access drugs have money and
connections with influential people. They can simply pick
up the phone, speak straight to a doctor, and can bypass
queues. When the government talked about 10 000 on
ARV, we were shocked as we didn't know any of these
beneficiaries. I must say this caused anger in us. Civil
servants are getting it, soldiers, and teachers are all first
priority. But the majority of Zambians are unemployed or
in the informal sectors and are not getting access. An
ordinary Zambian can go to the clinic; but you will find
that they are put on a never-ending waiting list. 
Chairperson, Network for Zambian People Living with HIV,
Lusaka, 2004
Universal access ‘for everyone who requires it according to
medical criteria’ is the clarion call of the WHO/UNAIDS 3 by 5
Initiative to extend life-preserving antiretroviral (ARV)
treatment to 3 million people by 2005.1 It follows in the wake
of sustained pressure by treatment activists and their allies
who exposed the ‘deafening silence’ of the more affluent in
their indifference toward people living with AIDS (PLWAs).2
Activist pressure has contributed to, and benefits from, efforts
to clarify the relationship between treatment and the right to
health. The availability of essential drugs is now regarded as
an integral dimension of the right to health, whose core
content includes treatment, and control of epidemics, as well
as prevention.3 The 3 by 5 Initiative has served to catalyse
international action on making treatment a reality for PLWAs
in low-resource settings.
For all of the distance covered and rapid progress
unquestionably being made, however, ARV treatment coverage
remains limited at 15% in developing and transitional
countries, and even lower in sub-Saharan Africa, at 11%.4
Universal access is still very much a distant goal. Nevertheless,
the efforts to scale up are already providing valuable
experiences.5 Among them is increased knowledge about what
scale-up efforts imply for equity in treatment access. In the
quotation above, a Zambian AIDS activist captures the
incredibly dispiriting sense of there being a ‘never-ending
waiting list’ for ARVs for the poor. Normative issues
concerning distribution and rationing of scarce resources have
been debated in health policy for a long time, but they have
received relatively little attention in the context of access to
ARVs.6 Scaling up ARVs takes place, after all, against a more
general backdrop of health interventions that ‘seldom reach
the poor’ and reflect a ‘skewed distribution of basic health
services within and between countries’.7
It is therefore critical to ask how the increase in resources and
new determination of governments and donors to expand
access to ARVs are being played out in countries characterised
by high levels of inequality. In other words, while universal
access is akin to a distant ship on the horizon, until this ship
comes in, it is important to identify how scaling up reinforces
or alleviates inequality.
This article explores how issues of equity and fairness can
receive greater attention as access to ARVs is scaled up. There
is an important role for human rights in levelling the
treatment playing field by ensuring that equality and non-
discrimination principles guide policies and programmes.
International human rights norms, standards, and instruments
have mapped out corresponding state obligations in an
increasingly concrete fashion.8 More specifically, the
International Guidelines on HIV/AIDS and Human Rights
examine these in the context of the HIV/AIDS epidemic.9 As
alluded to by other commentators, however, a broader
consideration is how human rights can and should interface
with systemic inequalities that create the political, social, and
H I V  M A N A G E M E N T  
ON A NEVER-ENDING WAITING LIST
Toward equitable access to
antiretroviral treatment? Experiences from Zambia
Peris Sean Jones, PhD
Research Fellow, Norwegian Centre for Human Rights
Universal access to antiretroviral (ARV) medication for HIV/AIDS is the clarion call of the WHO/UNAIDS 3 by 5 Initiative.
Treatment coverage, however, remains highly uneven. This sharpens the question of who exactly is accessing ARVs and whether
access is challenging inequality or reinforcing it. Issues of distributive justice have long been debated in health policy, but the
practical challenges of ARV distribution are relatively new. In exploring what a more equitable process of ARV distribution could
involve, this article draws on a human rights framework using case study material from Zambia.
Reprinted from Health and Human Rights (2005; 8(2)),
with permission.
THE SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE                                       DECEMBER 2006  27
economic exclusion of the poor and vulnerable.10 How we
move beyond human rights ‘wish lists’ of recommendations
concerning state obligations and toward actual
implementation is important in this regard. The challenges
involved in scaling up access to ARVs in Zambia illustrate
some of these broader concerns.
First, this article reviews the cornerstone 3 by 5 documents,
pointing out that they do not devote much attention to issues
of equity in access, and then reviews other documents,
including the proceedings of a World Health Organization
(WHO) consultation on equitable access to treatment.
Second, some of the practical dilemmas in seeking
redistributive justice are illustrated through the process of
setting criteria in national efforts to scale up in Zambia.
Discussion of particular barriers to access is included. 
Third, the article discusses systemic barriers that pose
challenges to determining a fair process for ARV distribution
that takes into account competing criteria.11 As important as a
fair process is, the influence of political (and discursive) power
in decision-making – even about fair process – may have been
underestimated. What appears to be critical from a human
rights perspective is that upholding state obligations requires
that individuals and their organisational representatives be
considered legitimate participants and active agents in the
process. Effective citizen participation, however, also requires
that participants are able to exert leverage over policy-making
decisions. Rights-based discourse and practice need to be
more explicit about the role of political and social
organisations in exercising and claiming rights. To that end, a
rights-based approach to development (RBD) has potential to
construct a politics of accountability capable of altering
relations between individuals and the state. For RBD to be
regarded as relevant and transformative, however, it has to
acknowledge and confront the complexity of specific sites of
social, economic, and political struggle over access to ARVs
and, more generally, service provision.
EXISTING CRITERIA FOR PATIENT SELECTION
An initial Internet-based search for ‘criteria’ for patient 
selection for HIV/AIDS medication returned search hits
indicating an overwhelming bias toward ‘clinical’, ‘ethical’
(concerning trials), and ‘low-cost’ DAI (drug access initiative –
that is, clinical) criteria. When ‘eligibility’ was added to the
search term, the hits tended to be grouped under ‘financial’,
‘medical’ and ‘therapeutic guidelines.’12 A subsequent search
through key UNAIDS and WHO documents revealed a striking
absence of equity-based criteria for patient selection. In the
cornerstone document, Scaling Up Antiretroviral Therapy in
Resource-Limited Settings, the focus is upon scientific
advances in the ARV field.13 As with 3 by 5 itself, the
fundamental consideration underpinning these documents is,
of course, the objective of broadening ARV access to 3 million
people by 2005.
The objective of expanding access, however, assumes that it
will ultimately achieve the goal of universal access ‘for
everyone who requires it according to medical criteria’.14 This is
a necessary and noble objective, but a significant barrier to
achieving it is the fact that services in resource-poor societies
are skewed toward those who are better off. Although WHO
refers to ‘protecting and serving vulnerable groups in
prevention and treatment programmes’, and, in fact, states in
1 of the 11 guiding principles for 3 by 5 that ‘the initiative will
make special efforts to ensure access to antiretroviral therapy
for people who risk exclusion because of economic, social,
geographical or other barriers’, the Initiative does not specify
how it will achieve equity or minimise unfairness. WHO
documents refer to better use of key ‘entry points’, such as
with patients with tuberculosis (TB), but the documents do not
detail means of prioritising social criteria.15 A discussion paper
prepared for a follow-up meeting on the implementation of
the United Nations 2001 Declaration of Commitment on
HIV/AIDS does, however, mention structural factors such as
lack of skilled health care workers and ‘the barriers to access
presented by cost-recovery mechanisms’.16
Barriers to access are invoked in some detail in rights-specific
documents such as the International Guidelines on HIV/AIDS
and Human Rights. The commentary on revised guideline
number 6 states that ‘… universal access requires that these
goods, services and information [that is, concerning
prevention, care and treatment] not only be available,
acceptable and of good quality but also within physical reach
and affordable for all’.17 It also identifies the need for positive
measures ‘to address factors that hinder equal access’, such as
poverty, migration, rural location, and ‘discrimination of
various kinds’. A fundamental omission within all of these
documents, however, is a detailed discussion about the kinds
of targeted measures required to ensure greater equity in
treatment access. The relatively limited attention given by
WHO to equity criteria in the 3 by 5 cornerstone documents
was to some extent supplemented by their Consultation on
Equitable Access to Treatment and Care for HIV/AIDS.
Contributions by the Pro-Poor Health Policy Team, and,
especially, by Daniels and Macklin, stressed the need for
‘careful decisions justified by principles of ethics and equity’ in
addressing the challenge of prioritising access to ARVs.18,19
With the backdrop of these documents in mind, the following
sections look at some of the dilemmas faced when treatment
access is scaled up, in the context of the challenges faced
within a particular country.
ZAMBIA: CONSIDERATIONS FOR CRITERIA SETTING
Greater consideration appears, in general, to be given to
clinical criteria rather than to ensuring a rights-based focus
upon equity. This practice raises the question of who should be
given priority in access to treatment and surfaces fundamental
issues of ethics, power, and political discourse. These dilemmas
and challenges can be better understood in a specific country
context.
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In Zambia, HIV/AIDS prevalence among people between 15
and 49 years of age is estimated to be over 16%. Over 1 million
people are estimated to be HIV-positive, of whom 54% are
women. It is currently estimated that 149 000 of these people
could benefit from ARVs.20 Since 2002, the government has
subsidised medication, surpassing the initial target of 10 000
Zambians on treatment by the end of 2003 at nine provincial
treatment centres. As of March 2005, however, the coverage
of approximately 23 000 people (including 2 000 in the private
sector treatment programmes), despite substantial progress
made over the past year, means that it appears highly unlikely
that the WHO and Zambian National AIDS Council target of
100 000 on treatment by the end of 2005 will be reached.21
Even if the target of 100 000 on treatment were reached, this
would still leave another 49 000 people without ARVs.
As is the case with many countries, attempts by the
government in Zambia to establish equitable criteria for ARV
distribution have proved inadequate, if not non-existent. The
situation in Zambia is similar to that in many countries where
HIV infection is prevalent, raising questions about means of
determining equity in access to ARVs. If only a fraction of
those in need can access treatment, how should decisions be
made about who should receive treatment first? In an effort to
establish criteria for the ARV selection process, the author
engaged in a short period of fieldwork in Zambia in 2004. The
purpose was to conduct interviews to elicit suggestions from
eight respondents selected for interview because they were
identified as key cross-sectoral actors in the scale-up of ARVs
in Zambia. Respondents were drawn from the non-
governmental (NGO) sector, including organisations with
representation on the board of the National AIDS Council,
such as the Network for Zambian People Living with HIV;
university-based researchers; and UN agencies such as WHO
and UNAIDS. Furthermore, as he was in Zambia, Dr Alex
Coutinho, Director of the AIDS Support Organization (TASO) in
Uganda, a prominent HIV/AIDS organisation, was available for
more general discussion of selection criteria issues.
Intended as a ‘snapshot’ of Zambian policy concerning
selection criteria in the context of rapid scaling up of ARV
treatment, the fieldwork was based upon structured interview
schedules using standardised questions put to each
respondent.22 Although government sector representatives
were unavailable for comment, an informal discussion was
held with a seconded employee at the Central Board of Health
concerning scale-up. A hospital, clinic, and local hospice were
also visited in Lusaka. Finally, a desk-based review of the print
media was undertaken prior to the fieldwork. Respondents
were asked to identify, as far as they were aware, the criteria
governing access to ARVs in Zambia and whether they
considered it satisfactory in terms of equity. Some of the
criteria in Table I were then used as prompts in the interviews.
Unprompted, all eight respondents consistently identified two
criteria that they believed were used to determine access to
ARVs. The first were the clinical criteria commonly associated
with eligibility for treatment. The second were economic
criteria. In other words, the imposition by government of cost-
recovery requirements – that is, the financial contribution that
PLWAs were required to make toward their ARVs, as well as
associated costs such as those for testing – was identified as
the fundamental barrier to access and the greatest engine of
inequity. The introduction of user fees for service provision
during the era of World Bank and International Monetary
Fund-inspired Structural Adjustment Programs, in the 1990s
in particular, has been identified, more generally, as a major
factor in undermining the health of the poor.23 In 2004, at the
time of the fieldwork, a range of cost barriers excluded the
poor from access to ARVs: a K40 000 (approximately US$9.00)
monthly contribution to medication, a K90 000 (approximately
US$21.00) contribution to the cost of a CD4 count, a K65 000
(approximately US$15.00) contribution to the cost of a liver
count, the K1 000 (approximately US$.23) contribution to the
cost of HIV testing at some voluntary counselling and testing
(VCT) sites, and the transportation costs for attending clinics
or hospital (K5 000 equals approximately US$1.00).24
In terms of social criteria used as prompts in interviews, there
was almost unanimity concerning respondent disapproval of
community selection panels due to concerns over misuse and
potential bias in selection. In addition, one respondent said
that to give preference for treatment to PLWAs with a greater
number of dependents was unacceptable: ‘But who is life
more valuable to? I am not going to say that I can die as my
neighbor has 10 dependents and I only have 2. Come on! It
should be available for whoever needs it.’25
In response to questions about who should receive priority in
ARV treatment, other respondents, such as Dr Coutinho,
claimed that criteria that extend beyond medical criteria
should be considered relevant only when determining
suitability of the patient for treatment. Thus, some degree of
disclosure of status to a friend or relative was considered
conducive to greater chances of adherence, perhaps through
encouragement of a ‘treatment buddy’. The issue of providing
privileged access to dependents could also be cast in this light.
Prioritising mothers and/or dependents, such as partners or
children, might greatly enhance openness and encourage
medical efficiency through mutual support. This might also
perhaps avoid situations where patients share their doses with
family members.
Clement Mfuzi, the Chairperson of the Network for Zambian
People Living with HIV, felt that there was a need to provide
priority access to those considered to be sicker than others: ‘I
know that not all of us can be on ARVs; but if I see someone
in hospital with advanced symptoms, then they should be first
because life is not replaceable.’26 If level of sickness were a key
consideration in determining who should be given priority in
access to ARV treatment, however, then those cared for at
home who are too sick to travel to hospitals and clinics would
have more of a moral claim to treatment. As the husband of
the director of a local hospice pointed out, ‘The problem with
clinics is that they don’t see those behind their wall’ – in other
words, they don't see the bed-ridden at home.27
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Some respondents emphasised the need to give children
priority access, while others, although to a lesser extent,
suggested that women should be given such consideration.
The WHO Deputy Country Representative in Zambia stressed
the ‘social good’ derived from targeting specific marginalised
groups with particularly high levels of infection, such as truck
drivers and sex workers.28 Finally, Mfuzi also raised the issue of
whether PLWAs who had been on drug trials, which often
ended suddenly, should get priority.
The issue of whether and where treatment should be
geographically concentrated also warrants consideration.
Building upon existing capacity generally reflects sound
health system principles; but doing so in the context of
ensuring equitable access to ARV treatment frequently limits
the focus to urban areas, which prevents those in rural areas
from receiving treatment. Thus, most ARV distribution efforts
in Zambia, for example, are geographically skewed, since
possibly half of all patients on ARVs are located in Lusaka, the
capital.29 Taking geographical coverage into consideration
when developing access guidelines might be advantageous,
however, if, for example, efforts are aimed at deliberately
targeting specific settlements or provinces chosen for their
particular disadvantages in terms of inequity.30 Many
respondents identified rural areas as having the greatest
degree of inequity in access.
As this discussion shows and as ongoing debates illustrate, the
process of setting access priorities is heavily value laden and
immensely complicated and therefore may require legal and
public health guidelines. Macklin attaches great significance
to consideration of competing ethical principles – in short, the
criteria that are chosen reflect different values and will have
different implications for who is eligible for ARV even though
these choices are not always equitable.31 Decisions about who
will or will not receive treatment will take place regardless of
whether specific criteria to ensure equity in access have been
established, but these determinations may well lack balance
and fairness.32
The following discussion examines how this process is being
played out in national ARV policy in Zambia.
SETTING NATIONAL CRITERIA AND SCALING UP ARV
IN ZAMBIA
Discussions of scaling up ARVs in Zambia must take place in
the context of more general challenges of low coverage, poor
quality, and insufficiently funded health care.33 A particular
concern is that ‘people afflicted with HIV/AIDS seldom have
adequate access to the necessary health care services,
including antiretroviral drugs, facilities and food’.34
According to a review of print media coverage of ARV-related
issues and fieldwork interviews about the extent to which civil
society had been consulted by government, there appears to
have been scant public debate concerning the criteria
governing access.
In 2002, the Zambian government made a first commitment to
making ARVs widely available through the public health
system, when it allocated K12 billion ($US 3 million at the
time) for the purchase of drugs intended for 10 000 people.
The lack of discussion between government officials and
members of civil society regarding access might have been the
result of a number of factors, including the fact that there
appear to have been few public information campaigns at the
time. Furthermore, the National HIV/AIDS policy remains in
draft form after over 3 years, which means that national
responses have lacked overarching policy definition.35
Although Zambia's Central Board of Health announced in
2003 that a country-wide HIV/AIDS drug rollout would begin
within 6 weeks of the announcement, one of the major PLWA
organisations, the Network for Zambian People Living with
HIV, commented that ‘[T]here is very little communication
between the government and AIDS NGOs on the matter’,
implying that the government had been in the process of
making policy decisions without consulting those who needed
the treatment the most.36 One respondent from an
organisation working on the legal aspects of HIV/AIDS
suggested that ‘The problem is that government came first
with saying “10 000” but without discussion of criteria used
to distribute ARVs. Even if it is free, then it won't get to the
grassroots – but nobody talks about it [that is, equity].’37
Apparently, the poor and powerless – those most in need of
treatment – were ‘completely left out of the process and [are]
still not aware of how their members will benefit’.38 The
Network for Zambian People Living with HIV was doubtful of
the government's commitment to including those most
marginalised.39
What little public debate about criteria for coverage did take
place tended to focus on the rural/urban divide and
emphasised that ‘poor Zambians who live in rural areas’
should ‘also benefit’.40 A number of people in prominent
positions also suggested that efforts to scale up access to
treatment should focus on women and girls.41 The level  of
public disquiet at the reluctance of government to discuss and
define eligibility criteria, however, seemed to eventually
prompt announcement of criteria to determine which of the
country’s HIV-positive people would benefit from the
accelerated drug roll-out.
In 2003, according to the Times of Zambia, Brian Chituwo, the
Minister of Health, stated that the new criteria were to be
implemented after ‘many people voiced concerns that the
drugs were apparently available only to “privileged people”‘.42
The new criteria would, according to Dr Chituwo, ‘ensure that
people get these drugs on the first-come, first-serve basis’.43
Access, according to the Minister, would require voluntary
testing and counselling and a clinical test to determine viral
load. Apparently those PLWAs with higher levels of immunity
would not receive the drugs but would instead receive
nutrition counselling. The only apparent concession to non-
clinical criteria came with the suggestion that mothers who
had been on mother-to-child transmission (MTCT) prevention
programmes would continue to receive drugs.44
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These considerations were apparently based upon WHO
guidelines and clearly prioritised ‘clinical’ over equity
considerations.45 All of the interview respondents tended to
agree that the criteria weighed heavily toward clinical aspects.
Arguably, as long as criteria remained biased toward clinical
issues, prioritisation was more of a ‘technical’ endeavor devoid
of equity considerations and was biased in favor of those who
were better off.
BIASED FAVORING PEOPLE [WITH GREATER
RESOURCES]
For the majority of Zambians living on less than a dollar per
day, the economic costs mentioned earlier represent a
considerable barrier to access. Many Zambians have the strong
impression that people who are ‘better off’ are the ones
getting access, whereas ‘ordinary’ Zambians are put on
apparently never-ending waiting lists. The perception that
ARVs cannot be accessed by the ‘average man on the street’
but rather only by civil servants is prevalent: ‘If I was an
average man on the street somewhere along Cairo Road [a
busy street in downtown Lusaka] then I would not appreciate
this [that is, prioritising civil servants for ARV treatment].’46
Although removing cost recovery appeared morally
imperative, some of the government's reasoning for adhering
to this policy is complicated and cannot be detailed here other
than to note that they claimed, for example, that cost recovery
would enable more people to be placed on treatment, as
supply would go further.47
Highlighting some of the problematic issues related to cost
recovery, the majority of respondents said that they had heard
of instances in which PLWAs had sought consultation at the
big hospitals in Lusaka (which, until 2004, were the only public
health facilities where ARVs were available), only to be asked
first whether or not they were employed – a direct implication
related to their ability to pay for services. The perception of
bias was also confirmed during the author’s observation at an
HIV/AIDS clinic at one of the largest hospitals in Lusaka, where
prominence was given not to HIV/AIDS-related posters and
information, but rather to a sign announcing that patients
needed to present a receipt of payment before consultation.
One respondent even suggested that a so-called fast-track
system existed, whereby faster access to ARVs was ensured if
the recipient was willing to pay more than the usual fee.
In addition to formal costs, one respondent raised the issue of
bribes, or so-called informal costs, claiming that the greatest
factor determining access at one particular hospital was
whether the patient was willing and able to pay ‘informal’
costs across the chain of personnel facilitating access to
ARVs.48
On numerous occasions, it was alleged that, over and above
their ability to pay, civil servants were given access priority. A
majority of respondents alluded to a tacit government policy
of procurement for civil servants, although it was unclear
where the funding was coming from. One respondent claimed
that she had met a teacher in a rural district who had told her
that ARVs were relatively easy to access, despite the immense
barrier of distance, because of a scheme introduced by the
Ministry of Education. The practice of privileging the employed
and civil servants was also noticeable in one of the first state
pilot ARV projects.49
Thus, it would appear that, although it is not an official public
policy, the Zambian government has allowed privileged access
to ARVs for state employees. Whatever the reasons for the
perception of class and geographical bias, it is a powerful and
lingering impression, which will continue in the absence of
public deliberation over equity considerations in Zambia.
In mid-2004, in a highly significant policy departure from cost
recovery, four clinics were able to start dispensing life-
prolonging AIDS drugs free of charge in Lusaka at Chelstone,
Kalingalinga, Matero, and Kanyama clinics. Again, however,
the decision to provide a patient with access to ARVs was
solely ‘based on clinical examination undertaken by staff in
clinics’.50 The Network for Zambian People Living with HIV
again voiced its concern that coverage needed to include rural
areas where ‘people were equally in need’, and also called for
free treatment for opportunistic infections in addition to the
ARV treatment being dispensed in the Lusaka clinics
mentioned.
The removal of cost barriers at these four clinics appeared to
have a dramatic impact. A visit to one of the clinics confirmed
the positive view of patient uptake of ARVs. A dispensary
nurse informed the author that ‘The response has been
overwhelming, everyone is coming, men, women, all ages and
the poorest. Some also came who could not continue to afford
payments elsewhere. Everyone who is eligible and willing gets
ARV.’51
This positive development therefore underscores the profound
significance of the announcement made in July 2005 by the
government of Zambia to provide ARVs and related services
‘free in all public health facilities’, as a massive step toward
greater equity.52 There was no mention, however, of equity
criteria in either the July 2005 announcement (other than
mention of free coverage for refugees) or the earlier
announcement of free access at the four clinics in Lusaka.
Scale-up of ARV in Zambia, like elsewhere, is a dynamic
process. The announcement to end cost recovery concerning
ARVs shows that the government now feels it has sufficient
donor funding to remove the costs. As scale-up increases,
more people come forward for treatment, and existing
patients return to collect medication once a month; human
resources, however, are inevitably stretched. As a result,
waiting lists are growing, with the implication that difficult
choices remain regarding selection in the context of ‘first
come, first served’.
The Zambian government thus appears to be committed to
making ARVs available. As many respondents pointed out,
however, and as a human rights approach confirms,
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availability is not the same as making ARVs accessible in
financial, geographical, and cultural terms.53 The principle of
equality is pivotal to the right to health, with emphasis placed
upon equality of access. A core obligation within this
framework is to ‘ensure equitable distribution of all health
facilities, goods and services’. The onus is therefore placed on
states through their obligation to take ‘positive measures’ that
enable and assist individuals and communities to enjoy the
right to health. Obligations to fulfil the right to health involve
‘appropriate legislative, administrative, budgetary, judicial,
promotional and other measures towards the full realization
of the right to health’.54 Achieving this requires a national
health policy with a detailed plan. With regard specifically to
HIV/AIDS, as mentioned earlier, Zambia’s national plan still
remains in draft form. With regard to ARVs, however, the draft
Zambian National Implementation Plan appears to reflect
considerable awareness of equity. Of the eight strategic
objectives, one is labelled ‘Strengthen the community role for
provision of ART’. Within this objective, a critical submeasure
under the sub-title ‘Promotion and protection of rights’
includes ‘… realization of the right to treatment, participation
in ethical and equitable patient selection and other decision-
making, protection of human rights and community oversight
of ART programs …’55
Table I summarises the range of criteria used to formulate
policy regarding selection of ARV recipients. The table was
compiled mainly from issues arising from the review of print
media, the 2004 interviews, as well as one of the few reviews
of selection criteria that currently exists.56
The Zambian government appears to be making gradual
progress in providing access to ARVs. Expanded local access,
removal of cost recovery, and an implementation plan that
includes equity issues are all significant policy landmarks in
scaling up ARV coverage. Despite these advances, however,
because an additional 120 000 PLWAs are still without
treatment, monitoring of access remains inadequate, and little
has been accomplished in developing targeted measures to
enhance equity – ensuring fairness in access to ARVs is of
continuing concern.
TOWARD EQUITY HOW?
Experiences in Zambia illustrate some of the highly complex 
issues associated with establishing criteria to ensure equitable
access to ARV treatment. Barriers to access in Zambia,
including poverty, distance, and social and political exclusion,
are also generally found in other regions where HIV is
prevalent. A fundamental aspect of rights-based equity in
health consists of minimising the presence of avoidable health
inequalities and barriers to access. Many observers suggest
that rather than an equal allocation of resources, such as
ARVs, equity implies the allocation of fair shares in resources.
In terms of mapping out guiding principles for equity-based
criteria, we can draw upon a well-known framework for the
right to health emphasising availability; financial,
geographical, and cultural accessibility; quality; and equality.57
State parties’ obligation to provide information about the
availability of services and public information programmes is
one step.58 Another particularly important recommendation is
to establish health indicators and benchmarks in order to
monitor the treatment scale-up process. States parties should
identify the factors and difficulties affecting implementation
of their obligations. In terms of ARVs, it is particularly
noticeable that disaggregated information of access, in terms
of male, female, age, urban, rural, socioeconomic status, and
most disadvantaged and vulnerable, is not available in Zambia.
Such data are critical in order to monitor who is getting
medication. The information could also be used to encourage
equality and non-discrimination and to target the most
vulnerable.
The obligations and recommendations stated in human rights
instruments and consideration of periodic reports to the UN
Committee on Economic, Social and Cultural Rights are useful
tools in minimising unfairness. There is a more fundamental
issue, however, concerning how to create a process that will be
more likely to lead to their implementation. The point is not
only that formal rights should be guaranteed and
institutionalised – legal redress and lobbying is hampered by
the non-justiciablity of socioeconomic rights and the lack of
an equality clause in the Constitution, but that a politics of
acquiring and transforming such rights is enabled.59,60
Decision-making with respect to equity considerations, for
example, would appear to cut across issues concerning
barriers to access. As suggested earlier, the difficulty in
balancing competing principles governing eligibility for ARVs,
according to Daniels, adds urgency to the requirement of a
‘fair process’ involving public debate and information about
the principles. Daniels mentions five key principles, of which,
one, stakeholder participation, is particularly relevant.61
According to Daniels, stakeholder participation is aimed at
building consensus on ‘mutually justifiable terms of
cooperation’.62 This is one interpretation of the role of
participation. It is generally agreed that PLWA and community
organisation participation in HIV/AIDS-related policies and
programmes is highly desirable. With respect to 3 by 5,
however, specific interpretations related to the degree and
nature of participation tend to vary across related policy
documents. In the 3 by 5 document, for example, great scope
is suggested for PLWA and community involvement in
advocacy, planning, and delivery because of the implicit
understanding that their participation in these activities will
produce more successful responses to HIV/AIDS.63
While so central to the 3 by 5 strategy, here, as elsewhere,
community involvement can also be regarded in much more
functional terms: it can be invaluable in providing input into
programme design and management, addressing critical
questions related to care, and encouraging adherence.64,65 In
some projects, as well as potentially acting as a buffer to the
‘development of local patronage or even corrupt practices’,
McCoy says, ‘community structures have also been established
to ratify and legitimize decisions about patient selection’.66 All
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of these considerations are undoubtedly vital to the success of
3 by 5. The benefits of community participation are thus
numerous and far reaching, and such involvement should
continue to be encouraged.
Despite the many positive aspects of community involvement,
however, limitations of participation at this level need to be
considered. In assessing the full impact of community
participation, one must first clarify the reasons for seeking
such involvement – is it considered a ‘means’ to deliver policy
objectives, or an ‘end’ in itself? Additionally, the terms need to
be clarified: does participation, for example, involve acting in
a consulting capacity, playing an advisory role, delivering
somebody else’s policy, or, more profoundly, transferring some
degree of power between stakeholders? According to Cooke
and Kothari, who summarise a collection of articles reflecting
on over 25 years’ experience of development projects, in all
likelihood, participation reinforces the status quo rather than
challenges it.67
While participation, on the one hand, is a principle integral to
human rights discourse, the latter usually fails to interface
with critical accounts of participation emerging in
development studies that identify co-option of participants
and/or lack of transfer of power to participants (or certain
individuals and groups of participants) due to institutional,
social, cultural, and political dynamics. A case in point is the
observation made by one interview respondent concerning a
TABLE I. SUMMARY OF SELECTION FOR TREATMENT CRITERIA
Comments
Most commonly used criteria, although even here there is debate with respect to
biomedical criteria, with evidence of a need for flexibility in criteria in low-resource
settings. But in the interests of equity, treatment policy should not be divorced from
consideration of additional criteria mentioned below.
Here it could be argued that it is more efficient to target those who already know their
status, as well as children and partners of pregnant women. But the problem is that
this penalises non-pregnant women. Medical efficiency, in terms of likelihood of
successful outcome, raises dilemmas in the context of the additional criteria stated
below.
This tends to exclude the poor and especially the poorest of the poor. Payments also
drain household resources and treatment may not be sustainable, hence patients may
have existing treatment terminated due to inability to pay.
Problems with ‘first come, first served’ include: bias toward people who are better
educated or informed, or those from urban areas, possibly biased toward men. Specific
measures are required to overcome barriers to access – for example, travel costs,
targeting females, also requiring awareness-raising, particularly through ‘treatment
literacy’?
Time-keeping and some disclosure may increase efficiency and adherence. 
Criteria concerning number of dependents would be unfair to those with fewer.
Eligibility through geography becomes problematic in the context of transitory
populations and creates unfairness in areas geographically excluded from treatment.
Community participation in selection committees appears transparent but may
encourage bias and/or corruption.
Many groups such as men who have sex with men, sex workers, orphans, migrant
workers, and refugees need special efforts because they are particularly marginalised
and often considered ‘undeserving’ by society.
An additional category includes the bed-ridden at home unable to get to a clinic and
requiring particular attention.
Other dilemmas include whether those patients who have been involved in drug trials
ending abruptly require special entitlement.
Overall, there is the medical efficiency argument (above) that basing selection criteria
partly on those most marginalised is not necessarily compatible with determining a
more efficient outcome. The counterargument is that specially targeted resources and
social support is required for marginalised groups.
Due to burden upon states of cost of absenteeism and death of civil servants, the latter
may be given preference for treatment to non-civil servants. This may also reflect a
regime’s political considerations regarding its support base.
Selection
Clinical




Patients considered to have higher probability of successful outcome with
treatment:
■ Those already receiving treatment through prevention of mother-to-
child transmission (MTCT) programmes and perhaps their partner
and/or children
■ And/or people already receiving TB treatment
■ Those already tested versus those not yet tested
Economic
Based upon patient ability to make a financial contribution for services
received
Social/geographical
■ ‘First-come, first-served’ basis
■ Patient’s punctuality in keeping appointments*
■ Degree of disclosure
■ PLWA’s number of dependents
■ Eligibility through local residency
■ Community selection committees
Ethical/rights-based
(priority given to the following)
■ Stigmatised social groups
■ Post-exposure prophylaxis for health care workers and women and
children exposed through rape or sexual abuse
■ Those too sick to travel to hospital/clinic†
■ Poorest of the poor
■ People whose drug trials end abruptly
Administrative/political
State employees getting preference
* Médicines sans Frontières (MSF), in sub-Saharan Africa, initially agreed to provide treatment to only those patients who were on time for three appointments, and if relevant, those who brought
a parent or guardian with whom they shared their status. In Khayelitsha, outside Cape Town in South Africa, MSF requires that patients be on time for four appointments and if necessary
undergo prior TB treatment, with the stated goal of achieving better outcomes for adherence to ARVs. The assessment of eligibility also includes a home visit to verify geographical eligibility,
disclosure criteria, and evidence of commitment to long-term therapy and safe sex practices. Preference is also considered on the basis of the number of dependents as well as health status,
with the very sick getting priority; income (the very poor receiving priority over those being able to afford treatment); and, as stated, disclosure and degree of political activism. Elsewhere,
eligibility committees are also considered, such as the multi-sectoral committee in the Benin Initiative, which determines anonymously who receives treatment and appropriate financial
contribution. (Sehonou in Attawell and Mundy, ibid.)
† In Zambia, the number of PLWAs who are sick at home and physically unable to attend clinics is very large. Most respondents were particularly concerned about PLWAs receiving home-based
care and how they would access treatment.
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public ‘consultation’ meeting undertaken by the Zambian
National AIDS Council, which he attended. The meeting had
the appearance of a participatory process, but in essence it
was a controlled process, with public participation
orchestrated merely to rubber-stamp decisions apparently
already taken concerning government policy.68 Furthermore, in
view of the problems with participation, while civil society is
represented on the board of the Zambian National AIDS
Council, the actual quality and effectiveness of the
participation upon decision-making processes requires closer
scrutiny. 
Development studies and practice, on the other hand, tend not
to emphasise equality or non-discrimination principles, nor do
they focus on the most vulnerable. Above all, the development
‘community’ tends to be more preoccupied with localised and
micro-developmental versions of participation in specific
projects.
There would therefore appear to be extremely fertile ground in
bridging developmental practice and experience with the
broader emphasis within human rights upon state obligations
and political and civil rights of excluded individuals and
groups. In the quest for greater equity, a rights-based
approach to development (RBD), arguably, therefore has the
exciting potential to combine both. 
‘A rights-based approach to development’, according to
Frankovits, ‘integrates the norms, standards and principles of
the international human rights framework into the plans,
policies and processes of development.’69 The approach
therefore impacts on national planning priorities by having
the ability to redirect resources and to militate against policies
that undermine the realisation of economic, social, and
cultural rights. The missing link for the transformative
potential for human rights in development is not so much
about asserting legal claims, as catalytic as they sometimes
can be. Rather, following Uvin, human rights should be
considered ‘tools that crystallize the moral imagination and
provide power in the political struggle, but do not substitute
for either’.70 The significance of a more political interpretation
of RBD is that participation and political rights are attached to
holding State parties – and other parties, including donors –
accountable and transparent in different institutional and
policy fora.
CONCLUSION
This article has shown that progressive realisation of access to 
ARVs in Zambia is getting medication to an ever-increasing
number of people. As praiseworthy as this rapid progress
undoubtedly is, equity issues are not being addressed
adequately in scaling up. Obligations and recommendations
drawing on Zambia’s compliance with the International
Covenant on Economic, Social and Cultural Rights (ICESCR)
are an important step toward enhanced equity in access to
ARVs. National laws and policies should be brought into line
with international human rights standards so that effective
remedies are available when human rights are violated. A first-
come, first-served approach to treatment, while intrinsically
‘fairer’, requires additional targeted measures to ensure equity.
Criteria setting is an important initial process, which does not
appear to have taken place in Zambia beyond clinical criteria.
Projects and programmes should clearly be planned and
implemented in ways that enable affected people to
participate. The removal of cost recovery is fundamental to
more equitable access. The recent announcement by the
Zambian government to provide free ARVs and related services
in all public sector facilities, requires, nonetheless, special
attention to target particularly excluded groups such as
people in rural areas, children, those too sick or poor to get to
clinics and, more generally, reversing a culture of exclusion of
the poor. The important role for information campaigns and
disaggregated data for monitoring access has also been
mentioned. It is also increasingly evident that local-level clinic
delivery of ARVs will be vital in providing more equitable
access but also, in doing so, circumvents rationing implicit in
hospital waiting lists.
More broadly, however, while 3 by 5 confronts structural
problems concerning under-resourced health systems, it is
also shaped by the prevailing (im-) balance of power between
donors and recipient countries, on the one hand, and state and
civil society within countries, on the other. One explanation for
the apparent neglect of equitable access may be that it would
entail reorientation of institutional, political, and social power
and resources away from the included to the excluded. It is
clear that synergy among communities and state and non-
state implementers can have a critical bearing upon ARV
policy interventions. A critical barometer of the success of
scaling up ARVs will be the extent to which institutional
structures in Zambia, as elsewhere, such as National AIDS
Councils and Global Fund Country Coordinating Mechanisms,
enable genuine and effective participation, which reflects
some degree of transfer of power to civil society decision-
making. Donors must be bolder in enabling this to happen
because in Zambia, thus far, general lack of co-operation, with
mutual suspicion between civil society and the state –
sometimes unwittingly assisted by donors and NGOs – results
in participation being a de-politicised and ‘technical’
endeavour. Otherwise, there is an additional concern that
governments are more accountable to donors than to civil
society.
To encourage accountability of duty bearers, civil society
actors, including social movements, must themselves be
enabled to scale up in order to participate above and beyond
the micro project level. It is here that greater dialogue between
the human rights and development communities concerning
participation could be fruitful. It could reinsert the role of
political and civil rights and state obligations in promoting an
equitable process of development but in a way in which
human rights interrogates, and consequently can alter, the
relationship between individual and government. Rights-
based approaches can provide a powerful platform in
catalysing action in order to challenge inequitable
government policy positions. This will make a tremendous
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difference to the prospects for equity in universal access to
ARV. It will also assist in democratising the broader social,
economic, and political forces of exclusion, of which the
HIV/AIDS epidemic is such a powerful expression.
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